Blood Pressure Response to Patterns of Weather Fluctuations and Effect on Mortality

Aubiniere-Robb, Louise; Jeemon, Panniyammakal; Hastie, Claire E.; Patel, Rajan K.; McCallum, Linsay; Morrison, David S.; Walters, Matthew; Dawson, Jesse; Sloan, William T.; Muir, Scott; Dominiczak, Anna F.; McInnes, Gordon T.; Padmanabhan, Sandosh

doi:10.1161/hypertensionaha.111.00686

Cited by 51 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under this condition, the excess of Ang II resulting from high losartan dosage, would be expected to react with the AT 2 R, so greatly enhancing the losartan-induced fall in BP (Figs. 4,5,8). To this extent, the present human study is supportive of most rodent studies, and this might encourage the development of AT 2 R agonists, including truncated Ang II fragments, as possible novel antihypertensive agents.…”

Section: Preprints 16supporting

confidence: 69%

“…While confirming the normal small summertime decline in daily BP readings, [1][2][3][4][5] this case study documents a profound summertime dosage-dependent sensitivity to the BP-lowering effect of losartan. That this may also apply to other antihypertensive medications was suggested by…”

Section: Reviewsupporting

confidence: 64%

“…In Japan, Hozawa et al 1 relied on the home BP measurements of volunteers, but had no information on medications. In their longitudinal study on individual subjects, Aubinière-Robb et al 4 relied on clinic measurements of treated hypertensive subjects, but had "incomplete prescribing data. "…”

Section: Seasonal Medication Hypersensitivitymentioning

confidence: 99%

“…[1][2][3][4][5] However, the declines are small (e.g. 5-10 mm Hg) and are not known to relate to a particular form or dose of antihypertensive therapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Seasonal dosage-dependent hypersensitivity to the angiotensin II receptor blocker, losartan. A case report and review

Forsdyke¹

2013

Preprint

View full text Add to dashboard Cite

Since it has been in clinical use for two decades, individual data permitting evaluation of the long-term treatment of hypertension with losartan, which blocks the dominant angiotensin-II receptor (AT 1 R), should now be available. In the present case, by dosage adjustment according to daily home blood pressure (BP) readings, a mild degree of hypertension discovered during routine examination was kept in the 130/80 (mm Hg) range over an 11 year period (2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013).In the early years, control was achieved with 12.5 -25.0 mg/day and dosage adjustment was seldom needed on a seasonal basis. However, on increasing to 50 mg/day, a profound downward adjustment to 0 -12.5 mg/day was required in hot weather. The adjustment may have prevented recurrence of drug-induced postural hypotension and renal colic. Whether the adjustment facilitated an increased nocturnal BP, as suggested by some ambulatory BP studies, was not examined. A working hypothesis, consistent with animal experiments, is that under conditions of heat-stress (e.g. vascular dilation, salt loss), there is increased expression of a countervailing, losartan-insensitive, receptor subtype (AT 2 R). By lowering BP in response to antiotensin-II, AT 2 R would facilitate fine-tuning of the AT 1 R-mediated vasoconstriction that supports BP when superficial veins dilate to enhance body cooling. This AT 2 R activity might be sufficient to explain a small summertime BP dip found in normal human subjects whose Ang II levels are not increased. The dip would be greatly enhanced when Ang II levels were increased at higher losartan dosages. Close monitoring of losartan dosage may be necessary for those living in, or travelling to, geographical regions where temperatures are seasonally or continually high, and for those engaging in activities that involve such exposure (e.g. hot yoga, Turkish baths).

show abstract

Section: Preprints 16supporting

confidence: 69%

Section: Reviewsupporting

confidence: 64%

Section: Seasonal Medication Hypersensitivitymentioning

confidence: 99%

“…[1][2][3][4][5] However, the declines are small (e.g. 5-10 mm Hg) and are not known to relate to a particular form or dose of antihypertensive therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Seasonal dosage-dependent hypersensitivity to the angiotensin II receptor blocker, losartan. A case report and review

Forsdyke¹

2013

Preprint

View full text Add to dashboard Cite

show abstract

“…While blood pressure is typically low during periods of rest and sleep, it can be high during periods of stress and exercise. Blood pressure also varies throughout the day depending on hormonal and other regulatory mechanisms and it shows longer-term variability due to seasonal and other environmental influences [3]. In addition, some organs, including the kidneys and the brain have sophisticated mechanisms to maintain constant perfusion pressures irrespective of systemic blood pressure [2].…”

Section: Introductionmentioning

confidence: 99%

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Delles

Carrick

Graham

et al. 2018

Expert Review of Proteomics

View full text Add to dashboard Cite

Introduction: Hypertension is a complex and multifactorial cardiovascular disorder. With different mechanisms contributing to a different extent to an individual’s blood pressure, the discovery of novel pathogenetic principles of hypertension is challenging. However, there is an urgent and unmet clinical need to improve prevention, detection, and therapy of hypertension in order to reduce the global burden associated with hypertension-related cardiovascular diseases.Areas covered: Proteomic techniques have been applied in reductionist experimental models including angiotensin II infusion models in rodents and the spontaneously hypertensive rat in order to unravel mechanisms involved in blood pressure control and end organ damage. In humans proteomic studies mainly focus on prediction and detection of organ damage, particularly of heart failure and renal disease. While there are only few proteomic studies specifically addressing human primary hypertension, there are more data available in hypertensive disorders in pregnancy, such as preeclampsia. We will review these studies and discuss implications of proteomics on precision medicine approaches.Expert commentary: Despite the potential of proteomic studies in hypertension there has been moderate progress in this area of research. Standardized large-scale studies are required in order to make best use of the potential that proteomics offers in hypertension and other cardiovascular diseases.

show abstract

Twenty years trends in mortality rates from stroke in Klaipeda

et al. 2016

View full text Add to dashboard Cite

BackgroundDuring the past decades, mortality from stroke decreased in many western European countries; however, changes concerning long‐term stroke mortality in eastern European countries are less evident.ObjectiveTo assess age‐ and gender‐specific trends in stroke mortality in Klaipeda (Lithuania) from 1994 to 2013.DesignDescriptive epidemiological study.Setting/subjectsPermanent population of Klaipeda.MethodsData on 2509 permanent residents of Klaipeda aged 35–79 years who died from stroke between 1994 and 2013 were gathered. Directly, age‐standardized (European population) stroke mortality rates were analyzed using joinpoint regression separately for specific age groups (35–64, 65–79, and 35–79 years) and by gender. Annual percentage change (APC) and 95% CIs were presented.ResultsStroke mortality in the 35‐ to 79‐year‐old age group peaked in 1994–1997, it then decreased by −9.9% (95% CI: −18.7, −0.2) yearly up until 2001 and leveled off by −0.2% (−5.1, 4.9) between 2001 and 2013. Among men aged 35–64 years, mortality decreased substantially by 12.8% (−21.5, −3.3) per year from 1994 to 2001 and turned positive by 6.3% (0.8, 12.1) between 2000 and 2013. Among women aged 35–64 years, mortality decreased significantly by 15.5% (−28.1, −0.7) from 1994 to 2000. There was evidence of recent plateauing of trends for 35‐ to 64‐year‐old women between 2000 and 2013. In the 65‐ to 79‐year‐old age group, mortality decreased from 1994 onward yearly by −5.5% (−7.9, −3.0) in women and by −3.3% (−5.6, −0.9) in men.ConclusionsJoinpoint regression revealed steadily decreasing trend in stroke mortality between 1994 and 2001. The decline in death rates flattened out in the recent decade. Mortality rates varied among age groups and were more pronounced in adults aged 35–64 years. It is essential to monitor and manage stroke risk factors, especially among middle‐aged population.

show abstract

Blood Pressure Response to Patterns of Weather Fluctuations and Effect on Mortality

Cited by 51 publications

References 34 publications

Seasonal dosage-dependent hypersensitivity to the angiotensin II receptor blocker, losartan. A case report and review

Seasonal dosage-dependent hypersensitivity to the angiotensin II receptor blocker, losartan. A case report and review

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Twenty years trends in mortality rates from stroke in Klaipeda

Contact Info

Product

Resources

About